Conclusions

In the INBUILD trial in subjects with progressive fibrosing ILDs other than IPF, fewer subjects treated with nintedanib than placebo had clinically relevant declines in FVC over 52 weeks.
These results further support the benefit of nintedanib on slowing the progression of ILD in subjects with chronic fibrosing ILDs and a progressive phenotype.